{"id":57913,"date":"2026-02-25T13:51:07","date_gmt":"2026-02-25T05:51:07","guid":{"rendered":"https:\/\/flcube.com\/?p=57913"},"modified":"2026-02-25T13:51:08","modified_gmt":"2026-02-25T05:51:08","slug":"sinomabs-first-in-class-il-25r-antibody-sm17-wins-nmpa-ind-approval-novel-ibd-therapy-enters-clinic","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57913","title":{"rendered":"SinoMab&#8217;s First\u2011in\u2011Class IL\u201125R Antibody SM17 Wins NMPA IND Approval \u2013 Novel IBD Therapy Enters Clinic"},"content":{"rendered":"\n<p><strong>SinoMab BioScience Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/3681:HKG\">HKG:\u202f3681<\/a>)<\/strong> announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved the <strong>Investigational New Drug (IND)<\/strong> application for <strong>SM17<\/strong>, a <strong>first\u2011in\u2011class (FIC)<\/strong> therapeutic candidate for <strong>inflammatory bowel disease (IBD)<\/strong>. The <strong>novel humanized IgG4\u2011\u03ba monoclonal antibody<\/strong> targets the <strong>interleukin\u201125 receptor (IL17RB)<\/strong>, offering a <strong>unique Type II inflammatory pathway mechanism<\/strong> with potential in <strong>ulcerative colitis (UC)<\/strong> and broader IBD indications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>SinoMab BioScience Limited (HKG:\u202f3681)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SM17<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>First\u2011in\u2011class humanized IgG4\u2011\u03ba monoclonal antibody<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>NMPA IND approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Inflammatory bowel disease (IBD)<\/td><\/tr><tr><td><strong>Primary Focus<\/strong><\/td><td>Ulcerative colitis (UC)<\/td><\/tr><tr><td><strong>Innovation Status<\/strong><\/td><td>First\u2011in\u2011class (FIC) \u2013 no approved competitors targeting IL\u201125R<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-type-ii-inflammatory-modulation\">Mechanism of Action \u2013 Type II Inflammatory Modulation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Function<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td>IL\u201125 receptor (IL17RB)<\/td><\/tr><tr><td><strong>Target Cells<\/strong><\/td><td>Type 2 innate lymphoid cells (ILC2s) and Th2 cells<\/td><\/tr><tr><td><strong>Upstream Trigger<\/strong><\/td><td>IL\u201125 \u2013 core Type II immune alarmin molecule<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Binding to IL17RB inhibits IL\u201125\u2011mediated signaling<\/td><\/tr><tr><td><strong>Downstream Effect<\/strong><\/td><td>Downregulation of key inflammatory cytokines: <strong>IL\u20114, IL\u20115, IL\u201113<\/strong><\/td><\/tr><tr><td><strong>Therapeutic Rationale<\/strong><\/td><td>Modulation of Type II inflammatory responses implicated in IBD pathogenesis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011Class Differentiation:<\/strong> SM17 is the <strong>first therapeutic candidate<\/strong> targeting the IL\u201125\/IL17RB axis, positioning SinoMab as a <strong>pioneer in a novel immunology pathway<\/strong> with no approved competitors.<\/li>\n\n\n\n<li><strong>IBD Unmet Need:<\/strong> Ulcerative colitis affects <strong>millions globally<\/strong>; existing therapies (anti\u2011TNF, anti\u2011integrin, JAK inhibitors) have efficacy limitations and safety concerns, creating demand for <strong>mechanistically novel alternatives<\/strong>.<\/li>\n\n\n\n<li><strong>Type II Inflammation Focus:<\/strong> The IL\u201125\/IL\u20114\/IL\u20115\/IL\u201113 axis is central to <strong>Type II immune responses<\/strong> increasingly implicated in IBD, asthma, and atopic diseases\u2014suggesting <strong>broad pipeline potential<\/strong> beyond UC.<\/li>\n\n\n\n<li><strong>Clinical Validation Opportunity:<\/strong> IND approval enables Phase I initiation to establish <strong>proof\u2011of\u2011mechanism<\/strong> and safety, with potential for <strong>fast\u2011track development<\/strong> if early efficacy signals emerge.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Global IBD Market<\/strong><\/td><td>Projected to exceed <strong>$25\u202fbillion<\/strong> by 2030, driven by biologic and small\u2011molecule innovation<\/td><\/tr><tr><td><strong>UC Treatment Paradigm<\/strong><\/td><td>Evolution toward personalized therapy based on inflammatory endotypes; Type II\u2011high patients may represent addressable subpopulation<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>No approved IL\u201125R inhibitors; SM17 competes with developmental pipeline rather than marketed products<\/td><\/tr><tr><td><strong>China Biotech Innovation<\/strong><\/td><td>NMPA IND approval validates SinoMab&#8217;s <strong>independent antibody discovery capabilities<\/strong> and novel target selection strategy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase I initiation, clinical efficacy outcomes, and commercial potential for SM17. Actual results may differ due to risks including safety signals in first\u2011in\u2011human studies, competitive program advancements, and IBD market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026022401184_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026022401184_c.\"><\/object><a id=\"wp-block-file--media-bb762cca-cfb2-4a6d-8dd2-01744ae46c6c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026022401184_c.pdf\">2026022401184_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026022401184_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-bb762cca-cfb2-4a6d-8dd2-01744ae46c6c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SinoMab BioScience Limited (HKG:\u202f3681) announced that China&#8217;s National Medical Products Administration (NMPA) has approved the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,62,1373,684],"class_list":["post-57913","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-approval-initiation","tag-hkg-3681","tag-sinomab-bioscience"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SinoMab&#039;s First\u2011in\u2011Class IL\u201125R Antibody SM17 Wins NMPA IND Approval \u2013 Novel IBD Therapy Enters Clinic - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"SinoMab BioScience Limited (HKG:\u202f3681) announced that China&#039;s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for SM17, a first\u2011in\u2011class (FIC) therapeutic candidate for inflammatory bowel disease (IBD). The novel humanized IgG4\u2011\u03ba monoclonal antibody targets the interleukin\u201125 receptor (IL17RB), offering a unique Type II inflammatory pathway mechanism with potential in ulcerative colitis (UC) and broader IBD indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57913\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SinoMab&#039;s First\u2011in\u2011Class IL\u201125R Antibody SM17 Wins NMPA IND Approval \u2013 Novel IBD Therapy Enters Clinic\" \/>\n<meta property=\"og:description\" content=\"SinoMab BioScience Limited (HKG:\u202f3681) announced that China&#039;s National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for SM17, a first\u2011in\u2011class (FIC) therapeutic candidate for inflammatory bowel disease (IBD). The novel humanized IgG4\u2011\u03ba monoclonal antibody targets the interleukin\u201125 receptor (IL17RB), offering a unique Type II inflammatory pathway mechanism with potential in ulcerative colitis (UC) and broader IBD indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57913\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-25T05:51:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-25T05:51:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57913#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57913\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SinoMab&#8217;s First\u2011in\u2011Class IL\u201125R Antibody SM17 Wins NMPA IND Approval \u2013 Novel IBD Therapy Enters Clinic\",\"datePublished\":\"2026-02-25T05:51:07+00:00\",\"dateModified\":\"2026-02-25T05:51:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57913\"},\"wordCount\":435,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Clinical trial approval \\\/ initiation\",\"HKG: 3681\",\"SinoMab BioScience\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57913#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57913\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57913\",\"name\":\"SinoMab's First\u2011in\u2011Class IL\u201125R Antibody SM17 Wins NMPA IND Approval \u2013 Novel IBD Therapy Enters Clinic - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-25T05:51:07+00:00\",\"dateModified\":\"2026-02-25T05:51:08+00:00\",\"description\":\"SinoMab BioScience Limited (HKG:\u202f3681) announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for SM17, a first\u2011in\u2011class (FIC) therapeutic candidate for inflammatory bowel disease (IBD). The novel humanized IgG4\u2011\u03ba monoclonal antibody targets the interleukin\u201125 receptor (IL17RB), offering a unique Type II inflammatory pathway mechanism with potential in ulcerative colitis (UC) and broader IBD indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57913#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57913\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57913#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SinoMab&#8217;s First\u2011in\u2011Class IL\u201125R Antibody SM17 Wins NMPA IND Approval \u2013 Novel IBD Therapy Enters Clinic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SinoMab's First\u2011in\u2011Class IL\u201125R Antibody SM17 Wins NMPA IND Approval \u2013 Novel IBD Therapy Enters Clinic - Insight, China&#039;s Pharmaceutical Industry","description":"SinoMab BioScience Limited (HKG:\u202f3681) announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for SM17, a first\u2011in\u2011class (FIC) therapeutic candidate for inflammatory bowel disease (IBD). The novel humanized IgG4\u2011\u03ba monoclonal antibody targets the interleukin\u201125 receptor (IL17RB), offering a unique Type II inflammatory pathway mechanism with potential in ulcerative colitis (UC) and broader IBD indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57913","og_locale":"en_US","og_type":"article","og_title":"SinoMab's First\u2011in\u2011Class IL\u201125R Antibody SM17 Wins NMPA IND Approval \u2013 Novel IBD Therapy Enters Clinic","og_description":"SinoMab BioScience Limited (HKG:\u202f3681) announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for SM17, a first\u2011in\u2011class (FIC) therapeutic candidate for inflammatory bowel disease (IBD). The novel humanized IgG4\u2011\u03ba monoclonal antibody targets the interleukin\u201125 receptor (IL17RB), offering a unique Type II inflammatory pathway mechanism with potential in ulcerative colitis (UC) and broader IBD indications.","og_url":"https:\/\/flcube.com\/?p=57913","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-25T05:51:07+00:00","article_modified_time":"2026-02-25T05:51:08+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57913#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57913"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SinoMab&#8217;s First\u2011in\u2011Class IL\u201125R Antibody SM17 Wins NMPA IND Approval \u2013 Novel IBD Therapy Enters Clinic","datePublished":"2026-02-25T05:51:07+00:00","dateModified":"2026-02-25T05:51:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57913"},"wordCount":435,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Clinical trial approval \/ initiation","HKG: 3681","SinoMab BioScience"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57913#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57913","url":"https:\/\/flcube.com\/?p=57913","name":"SinoMab's First\u2011in\u2011Class IL\u201125R Antibody SM17 Wins NMPA IND Approval \u2013 Novel IBD Therapy Enters Clinic - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-25T05:51:07+00:00","dateModified":"2026-02-25T05:51:08+00:00","description":"SinoMab BioScience Limited (HKG:\u202f3681) announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for SM17, a first\u2011in\u2011class (FIC) therapeutic candidate for inflammatory bowel disease (IBD). The novel humanized IgG4\u2011\u03ba monoclonal antibody targets the interleukin\u201125 receptor (IL17RB), offering a unique Type II inflammatory pathway mechanism with potential in ulcerative colitis (UC) and broader IBD indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57913#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57913"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57913#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SinoMab&#8217;s First\u2011in\u2011Class IL\u201125R Antibody SM17 Wins NMPA IND Approval \u2013 Novel IBD Therapy Enters Clinic"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57913"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57913\/revisions"}],"predecessor-version":[{"id":57915,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57913\/revisions\/57915"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}